These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 15607127)

  • 1. The novel phosphodiesterase 4 inhibitor, CI-1044, inhibits LPS-induced TNF-alpha production in whole blood from COPD patients.
    Ouagued M; Martin-Chouly CA; Brinchault G; Leportier-Comoy C; Depincé A; Bertrand C; Lagente V; Belleguic C; Pruniaux MP
    Pulm Pharmacol Ther; 2005; 18(1):49-54. PubMed ID: 15607127
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship between phosphodiesterase type 4 inhibition and anti-inflammatory activity of CI-1044 in rat airways.
    Pruniaux MP; Lagente V; Ouaged M; Bertin B; Moreau F; Julien-Larose C; Rocher MN; Leportier C; Martin B; Bouget A; Dubuit JP; Burnouf C; Doherty AM; Bertrand CP
    Fundam Clin Pharmacol; 2010 Feb; 24(1):73-82. PubMed ID: 19650853
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modulation of matrix metalloproteinase production from human lung fibroblasts by type 4 phosphodiesterase inhibitors.
    Martin-Chouly CA; Astier A; Jacob C; Pruniaux MP; Bertrand C; Lagente V
    Life Sci; 2004 Jul; 75(7):823-40. PubMed ID: 15183075
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of airway hyperresponsiveness and pulmonary inflammation by roflumilast and other PDE4 inhibitors.
    Wollin L; Bundschuh DS; Wohlsen A; Marx D; Beume R
    Pulm Pharmacol Ther; 2006; 19(5):343-52. PubMed ID: 16257550
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phosphodiesterase 4 inhibition of beta2-integrin adhesion caused by leukotriene B4 and TNF-alpha in human neutrophils.
    Meliton AY; Muñoz NM; Lambertino A; Boetticher E; Learoyd J; Zhu X; Leff AR
    Eur Respir J; 2006 Nov; 28(5):920-8. PubMed ID: 16807266
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cilomilast for COPD: results of a 6-month, placebo-controlled study of a potent, selective inhibitor of phosphodiesterase 4.
    Rennard SI; Schachter N; Strek M; Rickard K; Amit O
    Chest; 2006 Jan; 129(1):56-66. PubMed ID: 16424413
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of inhibition of PDE4 and TNF-alpha on local and remote injuries following ischaemia and reperfusion injury.
    Souza DG; Cassali GD; Poole S; Teixeira MM
    Br J Pharmacol; 2001 Nov; 134(5):985-94. PubMed ID: 11682446
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-inflammatory and utero-relaxant effects in human myometrium of new generation phosphodiesterase 4 inhibitors.
    Oger S; Méhats C; Barnette MS; Ferré F; Cabrol D; Leroy MJ
    Biol Reprod; 2004 Feb; 70(2):458-64. PubMed ID: 14561639
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phosphodiesterase-4 inhibitors as a novel approach for the treatment of respiratory disease: cilomilast.
    Kroegel C; Foerster M
    Expert Opin Investig Drugs; 2007 Jan; 16(1):109-24. PubMed ID: 17155857
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phosphodiesterase inhibitors in airways disease.
    Fan Chung K
    Eur J Pharmacol; 2006 Mar; 533(1-3):110-7. PubMed ID: 16458289
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Airway relaxant and anti-inflammatory properties of a PDE4 inhibitor with low affinity for the high-affinity rolipram binding site.
    Martin C; Göggel R; Dal Piaz V; Vergelli C; Giovannoni P; Ernst M; Uhlig S
    Naunyn Schmiedebergs Arch Pharmacol; 2002 Apr; 365(4):284-9. PubMed ID: 11919652
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cilomilast.
    Schachter EN
    Drugs Today (Barc); 2006 Apr; 42(4):237-47. PubMed ID: 16703120
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-inflammatory potential of the selective phosphodiesterase 4 inhibitor N-(3,5-dichloro-pyrid-4-yl)-[1-(4-fluorobenzyl)-5-hydroxy-indole-3-yl]-glyoxylic acid amide (AWD 12-281), in human cell preparations.
    Draheim R; Egerland U; Rundfeldt C
    J Pharmacol Exp Ther; 2004 Feb; 308(2):555-63. PubMed ID: 14610230
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The identification of a novel phosphodiesterase 4 inhibitor, 1-ethyl-5-{5-[(4-methyl-1-piperazinyl)methyl]-1,3,4-oxadiazol-2-yl}-N-(tetrahydro-2H-pyran-4-yl)-1H-pyrazolo[3,4-b]pyridin-4-amine (EPPA-1), with improved therapeutic index using pica feeding in rats as a measure of emetogenicity.
    Davis TG; Peterson JJ; Kou JP; Capper-Spudich EA; Ball D; Nials AT; Wiseman J; Solanke YE; Lucas FS; Williamson RA; Ferrari L; Wren P; Knowles RG; Barnette MS; Podolin PL
    J Pharmacol Exp Ther; 2009 Sep; 330(3):922-31. PubMed ID: 19498103
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phosphodiesterase (PDE) 7 in inflammatory cells from patients with asthma and COPD.
    Jones NA; Leport M; Holand T; Vos T; Morgan M; Fink M; Pruniaux MP; Berthelier C; O'Connor BJ; Bertrand C; Page CP
    Pulm Pharmacol Ther; 2007; 20(1):60-8. PubMed ID: 16427796
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cilomilast, a selective phosphodiesterase-4 inhibitor for treatment of patients with chronic obstructive pulmonary disease: a randomised, dose-ranging study.
    Compton CH; Gubb J; Nieman R; Edelson J; Amit O; Bakst A; Ayres JG; Creemers JP; Schultze-Werninghaus G; Brambilla C; Barnes NC;
    Lancet; 2001 Jul; 358(9278):265-70. PubMed ID: 11498212
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interleukin-10 does not mediate the inhibitory effect of PDE-4 inhibitors and other cAMP-elevating drugs on lipopolysaccharide-induced tumors necrosis factor-alpha generation from human peripheral blood monocytes.
    Seldon PM; Barnes PJ; Giembycz MA
    Cell Biochem Biophys; 1998; 29(1-2):179-201. PubMed ID: 9631245
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cilomilast: a second generation phosphodiesterase 4 inhibitor for asthma and chronic obstructive pulmonary disease.
    Giembycz MA
    Expert Opin Investig Drugs; 2001 Jul; 10(7):1361-79. PubMed ID: 11772257
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An update and appraisal of the cilomilast Phase III clinical development programme for chronic obstructive pulmonary disease.
    Giembycz MA
    Br J Clin Pharmacol; 2006 Aug; 62(2):138-52. PubMed ID: 16842388
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PDE4 inhibitors in COPD--a more selective approach to treatment.
    Vignola AM
    Respir Med; 2004 Jun; 98(6):495-503. PubMed ID: 15191033
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.